|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM149883951 |
| 003 |
DE-627 |
| 005 |
20250205182127.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0500.xml
|
| 035 |
|
|
|a (DE-627)NLM149883951
|
| 035 |
|
|
|a (NLM)15308121
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Banuelos, Scott J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.09.2004
|
| 500 |
|
|
|a Date Revised 15.11.2007
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Immunodeficient NOD mice engrafted with human peripheral blood mononuclear cells (PBMCs) were used in two models of human islet allograft rejection. Model one: human PBMCs were engrafted into chemically diabetic NOD-scid mice bearing established subrenal human islet allografts. Inflammation and often complete islet allograft rejection were observed. Model 2 incorporated three key advances. First, we developed a new immunodeficient recipient, NOD-RagI(null)Prf1(null) mice. Second, graft-lymphocyte interactions were optimized by intrasplenic co-transplantation of islets and human PBMC. Third, NOD-scid islets expressing human HLA-A2.1 were used as allograft targets. Diabetic NOD-RagI(null)Prf1(null) recipients of HLA-A2.1 transgenic mouse islets, alone or co-engrafted with HLA-A2-positive human PBMC, exhibited durable graft survival and euglycemia. Contrastingly, co-transplantation with HLA-A2-negative human PBMC led to islet graft rejection without evidence of graft-vs.-host disease (GVHD). We propose that diabetic NOD-RagI(null)Prf1(null) mice co-engrafted with HLA-A2 mouse transgenic islets and allogeneic human PBMC provide an effective in vivo model of human islet allograft rejection
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a HLA-A2 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a Pore Forming Cytotoxic Proteins
|2 NLM
|
| 650 |
|
7 |
|a Perforin
|2 NLM
|
| 650 |
|
7 |
|a 126465-35-8
|2 NLM
|
| 700 |
1 |
|
|a Shultz, Leonard D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Greiner, Dale L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Burzenski, Lisa M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gott, Bruce
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lyons, Bonnie L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rossini, Aldo A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Appel, Michael C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 112(2004), 3 vom: 12. Sept., Seite 273-83
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:112
|g year:2004
|g number:3
|g day:12
|g month:09
|g pages:273-83
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 112
|j 2004
|e 3
|b 12
|c 09
|h 273-83
|